Cargando…

Tiotropium Bromide: An Update

Tiotropium bromide is a once-daily inhaled anticholinergic bronchodilator. It works by blocking the muscarinic receptors in airway smooth muscle. Tiotropium has a wide therapeutic margin, due to its poor gastrointestinal absorption and its very low systemic bioavailability. The drug is mainly indica...

Descripción completa

Detalles Bibliográficos
Autor principal: Heredia, Josep Lluis
Formato: Texto
Lenguaje:English
Publicado: Bentham Open 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684714/
https://www.ncbi.nlm.nih.gov/pubmed/19461900
http://dx.doi.org/10.2174/1874306400903010043
_version_ 1782167260008284160
author Heredia, Josep Lluis
author_facet Heredia, Josep Lluis
author_sort Heredia, Josep Lluis
collection PubMed
description Tiotropium bromide is a once-daily inhaled anticholinergic bronchodilator. It works by blocking the muscarinic receptors in airway smooth muscle. Tiotropium has a wide therapeutic margin, due to its poor gastrointestinal absorption and its very low systemic bioavailability. The drug is mainly indicated in COPD patients. Clinically relevant outcomes such as significant improvements in spirometry, hyperinflation, dyspnea, heath status, acute exacerbations and mortality have been consistently observed in tiotropium clinical trials, and the drug has been shown to reduce the risk of mortality due to cardiac-vascular disease and respiratory failure. The main side effect reported is dryness of the mouth. Some subgroups of asthmatics also seem to respond to anticholinergic drugs: among them, those with the Arg/Arg genotype for the β2-adrenergic receptor and those with a high percentage of neutrophils in sputum.
format Text
id pubmed-2684714
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Bentham Open
record_format MEDLINE/PubMed
spelling pubmed-26847142009-05-21 Tiotropium Bromide: An Update Heredia, Josep Lluis Open Respir Med J Article Tiotropium bromide is a once-daily inhaled anticholinergic bronchodilator. It works by blocking the muscarinic receptors in airway smooth muscle. Tiotropium has a wide therapeutic margin, due to its poor gastrointestinal absorption and its very low systemic bioavailability. The drug is mainly indicated in COPD patients. Clinically relevant outcomes such as significant improvements in spirometry, hyperinflation, dyspnea, heath status, acute exacerbations and mortality have been consistently observed in tiotropium clinical trials, and the drug has been shown to reduce the risk of mortality due to cardiac-vascular disease and respiratory failure. The main side effect reported is dryness of the mouth. Some subgroups of asthmatics also seem to respond to anticholinergic drugs: among them, those with the Arg/Arg genotype for the β2-adrenergic receptor and those with a high percentage of neutrophils in sputum. Bentham Open 2009-04-14 /pmc/articles/PMC2684714/ /pubmed/19461900 http://dx.doi.org/10.2174/1874306400903010043 Text en © Josep Lluis Heredia; Licensee Bentham Open. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Heredia, Josep Lluis
Tiotropium Bromide: An Update
title Tiotropium Bromide: An Update
title_full Tiotropium Bromide: An Update
title_fullStr Tiotropium Bromide: An Update
title_full_unstemmed Tiotropium Bromide: An Update
title_short Tiotropium Bromide: An Update
title_sort tiotropium bromide: an update
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684714/
https://www.ncbi.nlm.nih.gov/pubmed/19461900
http://dx.doi.org/10.2174/1874306400903010043
work_keys_str_mv AT herediajoseplluis tiotropiumbromideanupdate